Germany · Delayed Price · Currency is EUR XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of EUR 59.68 million. The enterprise value is -67.41 million.
| Market Cap | 59.68M |
| Enterprise Value | -67.41M |
Important Dates
The last earnings date was Monday, November 17, 2025.
| Earnings Date | Nov 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 30.49M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 37.41% |
| Owned by Institutions (%) | 9.84% |
| Float | 19.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.71 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 3.32 |
Financial Position
The company has a current ratio of 41.78
| Current Ratio | 41.78 |
| Quick Ratio | 41.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -118.76 |
Financial Efficiency
Return on equity (ROE) is -16.23% and return on invested capital (ROIC) is -11.74%.
| Return on Equity (ROE) | -16.23% |
| Return on Assets (ROA) | -11.34% |
| Return on Invested Capital (ROIC) | -11.74% |
| Return on Capital Employed (ROCE) | -20.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -282,382 |
| Employee Count | 92 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid 100,571 in taxes.
| Income Tax | 100,571 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.77% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.77% |
| 50-Day Moving Average | 2.01 |
| 200-Day Moving Average | 2.39 |
| Relative Strength Index (RSI) | 43.34 |
| Average Volume (20 Days) | 280 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.56M |
| Pretax Income | -24.75M |
| Net Income | -24.85M |
| EBITDA | -28.07M |
| EBIT | -29.56M |
| Earnings Per Share (EPS) | -0.82 |
Balance Sheet
The company has 125.60 million in cash and n/a in debt, giving a net cash position of 125.60 million.
| Cash & Cash Equivalents | 125.60M |
| Total Debt | n/a |
| Net Cash | 125.60M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 142.40M |
| Book Value Per Share | 4.67 |
| Working Capital | 123.91M |
Cash Flow
In the last 12 months, operating cash flow was -20.04 million and capital expenditures -288,930, giving a free cash flow of -20.32 million.
| Operating Cash Flow | -20.04M |
| Capital Expenditures | -288,930 |
| Free Cash Flow | -20.32M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XBiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -41.64% |
| FCF Yield | -34.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |